NEOPROBE RIGSCAN CR49 BIOLOGIC APPLICATION TO BE SUBMITTED IN 45-60 DAYS, FIRM SAYS; SYSTEM DETECTS 21% MORE TUMORS IN METASTATIC COLORECTAL CANCER
This article was originally published in The Gray Sheet
Executive Summary
Neoprobe expects to submit a biologic licensing application for its RIGScan CR49 for the detection of metastatic colorectal cancer within the next 45-60 days, the company says.